scholarly journals Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: Experience of 733 cases

The Breast ◽  
2012 ◽  
Vol 21 (5) ◽  
pp. 635-640 ◽  
Author(s):  
Chiara Trentin ◽  
Valeria Dominelli ◽  
Patrick Maisonneuve ◽  
Simona Menna ◽  
Barbara Bazolli ◽  
...  
2012 ◽  
Vol 12 (5) ◽  
pp. 378-381
Author(s):  
Olivier Brouckaert ◽  
Anneleen Reynders ◽  
Kathleen Vanderstappen ◽  
Ann Smeets ◽  
Ann Hoeben ◽  
...  

ISRN Oncology ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Andrei Dobrescu ◽  
Monique Chang ◽  
Vatsala Kirtani ◽  
George K. Turi ◽  
Randa Hennawy ◽  
...  

Background. To our knowledge, the hormone receptor status of noncontiguous ductal carcinoma in situ (DCIS) occurring concurrently in ER/PgR-negative invasive cancer has not been studied. The current study was undertaken to investigate the ER/PgR receptor status of DCIS of the breast in patients with ER/PgR-negative invasive breast cancer. Methods. We reviewed the immunohistochemical (IHC) staining for ER and PgR of 187 consecutive cases of ER/PgR-negative invasive breast cancers, collected from 1995 to 2002. To meet the criteria for the study, we evaluated ER/PgR expression of DCIS cancer outside of the invasive breast cancer. Results. A total of 37 cases of DCIS meeting the above criteria were identified. Of these, 16 cases (43.2%) showed positive staining for ER, PgR, or both. Conclusions. In our study of ER/PgR-negative invasive breast cancer we found that in 8% of cases noncontiguous ER/PR-positive DCIS was present. In light of this finding, it may be important for pathologists to evaluate the ER/PgR status of DCIS occurring in the presence of ER/PgR-negative invasive cancer, as this subgroup could be considered for chemoprevention.


2020 ◽  
Vol 254 ◽  
pp. 378-383
Author(s):  
Lauren R. Strang ◽  
James Sun ◽  
Weihong Sun ◽  
David Boulware ◽  
John V. Kiluk ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document